Zobrazeno 51 - 60
of 112
pro vyhledávání: '"Theodore F, Logan"'
Autor:
Charles A. Linker, Robert C. Barrier, David Avigan, Theodore F. Logan, Susan Halabi, Philip L. McCarthy, Kim Margolin, Brian I. Rini, Walter M. Stadler, Eric J. Small
Publikováno v:
Biology of Blood and Marrow Transplantation. 12:778-785
A graft-versus-tumor effect through nonmyeloablative allogeneic stem cell transplantation (N-SCT) in metastatic renal cell carcinoma (RCC) has been reported. An Intergroup phase II trial was undertaken to define further the feasibility, toxicity and
Publikováno v:
Current Oncology Reports. 8:114-119
Interleukins 18 and 21 have been described, and the effect of each upon immune response and experimental tumors in animals has been the subject of much recent work. Both interleukins have shown antitumor effects in animals, which in some models are s
Autor:
Mark A. Green, Theodore F. Logan, Jacob A. Eitel, Yen Ng, Gary D. Hutchins, Jeffrey L. Lacy, Carla J. Mathias, James W. Fletcher
Publikováno v:
Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 56(1)
This study was undertaken to demonstrate the feasibility of whole-body (62)Cu-ethylglyoxal bis(thiosemicarbazonato)copper(II) ((62)Cu-ETS) PET/CT tumor perfusion imaging in patients with metastatic renal carcinoma and to validate (62)Cu-ETS as a quan
Autor:
Bruce G. Redman, Elizabeth R. Plimack, Ulka N. Vaishampayan, Theodore F. Logan, Kim Margolin, David F. McDermott, Timothy M. Kuzel, Michael R. Harrison, Robert J. Motzer, Hans J. Hammers, Ian M. Waxman, Brian I. Rini, Alexandre Lambert, Saby George, Harry A. Drabkin
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 33(13)
Purpose Nivolumab is a fully human immunoglobulin G4 programmed death–1 immune checkpoint inhibitor antibody that restores T-cell immune activity. This phase II trial assessed the antitumor activity, dose-response relationship, and safety of nivolu
Autor:
Alexandra S. Bailey, Jeffrey A. Sosman, Su Chun Cheng, Bradley C. Leibovich, Michael Ka Keu Wong, Rupal S. Bhatt, Eugene D. Kwon, Leslie Oleksowicz, Joseph I. Clark, Leonard Joseph Appleman, Sabina Signoretti, Robert A. Figlin, Marc S. Ernstoff, David F. McDermott, Ulka N. Vaishampayan, Nikhil I. Khushalani, James W. Mier, Kim Margolin, Brendan D. Curti, Theodore F. Logan, David J. Panka, Allan J. Pantuck, Janice P. Dutcher, Fairooz F. Kabbinavar, Michael B. Atkins, Arie S. Belldegrun, Meredith M. Regan
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research, vol 21, iss 3
Purpose: High-dose aldesleukin (HD IL2) received FDA approval for the treatment of metastatic renal cell carcinoma (MRCC) in 1992, producing a 14% objective response rate (ORR) and durable remissions. Retrospective studies suggested that clinical and
Autor:
Janice P. Dutcher, Fred Immermann, Donna K. Slonim, Andrew J. Dorner, Manuel Hidalgo, William L. Trepicchio, Bonnie Marshall, Theodore F. Logan, Gary Dukart, Andrew Strahs, Michael E. Burczynski, Walter M. Stadler, Gary R. Hudes, Natalie C. Twine
Publikováno v:
Clinical Cancer Research. 11:1181-1189
Purpose: Given their accessibility, surrogate tissues, such as peripheral blood mononuclear cells (PBMC), may provide potential predictive biomarkers in clinical pharmacogenomic studies. In leukemias and lymphomas, the prognostic value of peripheral
Autor:
Richard Bihrle, Theodore F. Logan, Michael O. Koch, Ashraf A. Mosharafa, Arieh L. Shalhav, Thomas A. Gardner, Richard S. Foster
Publikováno v:
Urology. 62:636-640
Objectives To report on the short-term morbidity of radical nephrectomy in 32 patients with poorer performance status and more advanced primary renal cell carcinoma (RCC). Nephrectomy followed by immunotherapy has been shown to improve survival in se
Autor:
Theodore F. Logan
Publikováno v:
Facial Plastic Surgery Clinics of North America. 11:75-85
Publikováno v:
Bone Marrow Transplantation. 30:805-812
Nonablative hematopoietic cell transplantation (HCT) is becoming a preferred treatment for those recipients in whom the potential toxicity risk of standard ablative allogeneic therapy may be unacceptable. Graft-versus-malignancy effects may be genera
Autor:
Nikhil I. Khushalani, Alice P. Chen, Paul Frankel, Primo N. Lara, John M. Kirkwood, Ahmad A. Tarhini, Christopher Ruel, Sanjay Awasthi, Theodore F. Logan, David F. McDermott, Timothy M. Kuzel, Marc S. Ernstoff, Kim Margolin, Hussein Abdul-Hassan Tawbi
Publikováno v:
Cancer Research. 77:3827-3827
Background: IL-2 plays a central role in antitumor immunity. VEGF plays a critical role in angiogenesis and host innate and adaptive immunity. High baseline serum VEGF was associated with non-response to IL-2. Z, a high-affinity soluble decoy VEGF re